Clinical trials: Chronic Obstruct Airways Disease
Pulmonary Disease, Chronic Obstructive (COPD)
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.
- Trial name
- NCT07039669
- Testing
- 611
- Where
- 4 sites in China
- Volunteers
- 594 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to evaluate the effect of tiotropium on gross muscular efficiency
- Trial name
- NCT02172794
- Testing
- Tiotropium, Salmeterol
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
COPD, Chronic Obstructive Pulmonary Disease
Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD
The symptoms associated with COPD include overproduction of mucus and inflammation in the lungs. Overproduction of mucus results in impaired lung function and it encourages bacterial growth and associated COPD exacerbations.
- Trial name
- BREATH-1 (NCT00648245)
- Testing
- BIO-11006 Inhalation Solution, BIO-11006
- Where
- 14 sites in United States
- Volunteers
- 172 people
- Sponsor
- BioMarck Pharmaceuticals, Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive pulmonary disease.
- Trial name
- INSIST (NCT00821093)
- Testing
- Indacaterol 150 µg, Salmeterol 50 µg
- Where
- 144 sites in United States, Czechia and 6 more
- Volunteers
- 1,123 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.
The present trial is conducted to further assess the efficacy by means of serial spirometry, safety and tolerability of three doses of aclidinium bromide administered twice a day compared to previously approved BID drug…
- Trial name
- NCT01120093
- Testing
- Aclidinium bromide 100 μg bid, Aclidinium bromide 200 μg bid, Aclidininum bromide 400 μg bid
- Where
- 11 sites in Belgium, Germany
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Obesity Hypoventilation Syndrome, Obstructive Sleep Apnea
Simplus and Eson Non-Invasive Ventilation (NIV) Evaluation - Germany
This investigation is designed to evaluate the performance, comfort and ease of use of the Simplus and Eson masks amongst NIV patients who are currently on Bi-level therapy
- Conditions
- Obesity Hypoventilation Syndrome, Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Neuromuscular Disease
- Trial name
- NCT02726048
- Testing
- Simplus/Eson
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Fisher and Paykel Healthcare
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the safety and efficacy of QVA149 in patients with moderate to severe COPD.
- Trial name
- NCT00570778
- Testing
- indacaterol/glycopyrrolate, indacaterol
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 154 people
- Sponsor
- Novartis Pharmaceuticals
Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease
Study on Drug Interactions Affecting the Pharmacokinetics of RSS0343 Tablet
This study is a single-center, single-sequence, self-controlled, open design, aiming to investigate the effects of rifampicin and clarithromycin on the pharmacokinetics of RSS0343 in humans.
- Trial name
- NCT07696091
- Testing
- RSS0343 Tablet; Rifampicin Capsules, RSS0343 Tablet; Clarithromycin Tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Reistone Biopharma Company Limited
Pulmonary Disease, Chronic Obstructive
A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study to demonstrate the comparability of two puffs of Combivent hydrofluoroalkane (HFA) inhalation aerosol (18 mcg ipratropium bromide/100 mcg albuterol sulfate / per puff) to two puffs of the marketed chlorofluorocarbon (CFC)…
- Trial name
- NCT02182674
- Testing
- Combivent HFA, Combivent (CFC)
- Volunteers
- 66 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices
This is a randomised, open-label, placebo, crossover, multicentre study with a single visit. The study will comprise five sub-studies.
- Trial name
- NCT02184624
- Testing
- ELLIPTA, DISKUS/ACCUHALER, MDI
- Where
- 8 sites in Netherlands, United Kingdom
- Volunteers
- 569 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium
The objective of this study is to assess the daily variation in bronchodilator response to an inhaled short acting beta2-agonist (albuterol/salbutamol) and an inhaled short acting anticholinergic (ipratropium) individually and…
- Trial name
- NCT01691482
- Testing
- Albuterol/salbutamol, Ipratropium
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a randomized, double-blind, multi-dose, parallel group trial which will assess the pharmacodynamic response of fluticasone propionate and formoterol fumarate in subjects with COPD.
- Trial name
- NCT01168310
- Testing
- Fluticasone Propionate/Formoterol Fumarate, Formoterol Fumarate
- Where
- 23 sites in United States
- Volunteers
- 468 people
- Sponsor
- Dey
Pulmonary Disease, Chronic Obstructive
Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
This is a multi-center, randomized, double-blind, parallel-group study. The FF/VI inhalation powder once daily and VI inhalation powder once daily will be evaluated in subjects with COPD over 156 weeks.
- Trial name
- NCT01957150
- Testing
- Fluticasone Furoate/Vilanterol, Vilanterol
- Where
- 45 sites in United States, Canada and 3 more
- Volunteers
- 283 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The objective of the present study is to establish the safety and efficacy of multiple administrations of Prochymal™(ex-vivo cultured human adult mesenchymal stem cells) in participants with moderate to severe chronic obstructive…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
- Trial name
- NCT00683722
- Testing
- Prochymal™
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- Mesoblast, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.
- Trial name
- NCT02518139
- Testing
- TD-4208, Tiotropium
- Where
- United States
- Volunteers
- 1,060 people
- Sponsor
- Mylan Inc.
Pulmonary Disease, Chronic Obstructive
Clinical and Economic Burden of Patients With Chronic Obstructive Pulmonary Disease in a Medicaid Population
Reports suggest that the Medicaid population includes a higher percentage of smokers than the general population. A high prevalence of smokers in a population is likely to lead to a higher burden of chronic obstructive pulmonary…
- Trial name
- NCT01615783
- Testing
- Subjects with COPD, Subjects without COPD
- Volunteers
- 40,884 people
- Sponsor
- GlaxoSmithKline
COPD
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the dose response relationship among four doses of indacaterol as well as placebo delivered via the TWISTHALER® device.
- Trial name
- NCT00557466
- Testing
- indacaterol, formoterol, short acting β2- agonist
- Where
- 75 sites in Argentina, Belgium and 15 more
- Volunteers
- 568 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Danish Quality Assurance Project on Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (COPD) in Outpatient Lung Clinics
Danish Quality Assurance Project on Diagnosis and Treatment of COPD in Outpatient Lung Clinics
- Trial name
- NCT00268866
- Testing
- Education
- Volunteers
- 1,820 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease COPD
Realize the Current Situation of COPD Patients in China
This is a multi-centre, prospective, observational study to realize the current situation of COPD patients in China. About 5000 COPD patients will be enrolled from 50 participating sites around China and followed up for one year.
- Trial name
- REAL (NCT03131362)
- Where
- China
- Volunteers
- 5,020 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)
The aim of the study is to investigate the effect of roflumilast (APTA-2217) on lung function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily.
- Trial name
- NCT00242294
- Testing
- Roflumilast
- Where
- Japan
- Volunteers
- 570 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.